ArticlemSphere2022
Elimination of LRVs Elicits Different Responses in
Article in mSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Miltefosine and emerging Leishmania (Mundinia) in Southeast Asia: Molecular insights, therapeutic challenges, and future strategic implementation.PLoS neglected tropical diseases · 2026Review
- Leishmania major virulence attenuation in vitro: An old conundrum revisited in the omics era.PLoS neglected tropical diseases · 2026Article
- Harnessing controlled human infection models to accelerate vaccine development for neglected tropical diseases: Lessons from leishmaniasis.European journal of clinical investigation · 2026Review
- Review
- Comparative histopathological and immunological analysis of LRV2-positive and LRV2-negative Leishmania tropica in a BALB/c mouse cutaneous leishmaniasis model.Parasitology research · 2025Article
- A novel strain of Leishmania braziliensis harbors not a toti- but a bunyavirus.PLoS neglected tropical diseases · 2024Article
- Detection of Leishmania RNA Virus 2 (LRV2) among Clinical Isolates of Leishmania Major in Four Endemic Regions of Iran.Acta parasitologica · 2024Article
- Transcriptomics analysis highlights potential ways in human pathogenesis in Leishmania braziliensis infected with the viral endosymbiont LRV1.PLoS neglected tropical diseases · 2024Article
- The consequences of viral infection on protists.Communications biology · 2024Review
- Evolution of RNA viruses in trypanosomatids: new insights from the analysis of Sauroleishmania.Parasitology research · 2023Article
- Diversity of RNA viruses in the cosmopolitan monoxenous trypanosomatid Leptomonas pyrrhocoris.BMC biology · 2023Article
- Revisiting epidemiology of leishmaniasis in central Asia: lessons learnt.Parasitology · 2023Review
- First report of putative Leishmania RNA virus 2 (LRV2) in Leishmania infantum strains from canine and human visceral leishmaniasis cases in the southeast of Brazil.Memorias do Instituto Oswaldo Cruz · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniaviruses (LRVs) have been demonstrated to enhance progression of leishmaniasis, a vector-transmitted disease with a wide range of clinical manifestations that is caused by flagellates of the genus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.